摘要
目的观察有华法林抗栓指征的房颤患者,冠状动脉支架植入术后,联合华法林、替格瑞洛双重抗栓治疗的疗效及安全性。方法选取2013年5月—2014年9月冠心病合并心房颤动在泰州市人民医院行PCI术患者110例,随机分为观察组(T组,n=55)和对照组(C组,n=55)。术后T组给予替格瑞洛联合华法林治疗,C组给予氯吡格雷联合华法林治疗。治疗后对患者进行随访12个月,观察比较两组患者出血(颅内出血或临床可见出血)及不良心血管事件(再发心肌梗死,支架内血栓,再次PCI,缺血性脑卒中,短暂性脑缺血发作,血管栓塞原因相关或心脏缺血性的死亡)发生情况。结果 T组和C组不良心血管事件的发生率比较,差异无统计学意义(9.1%比10.9%,P=0.749)。T组和C组总出血发生率比较,差异无统计学意义(14.5%比12.7%,P=0.779)。结论替格瑞洛联合华法林与氯吡格雷联合华法林治疗冠心病合并心房颤动患者抗栓疗效及安全性相似。
Objective To observe the effect and safety of combined ticagrelor and warfarin antithrombus therapy in patients after the coronary artery stent implantation with indications of warfarin anticoagulant. Methods Totally 110 cases of coronary heart disease complicated with atrial fibrillation in our hospital from May 2013 to September 2014 were selected. Patients were randomly divided into the observation group（ T gloup,n = 55） and the control group（ C group,n =55）. The observation group was given Ticagrelor combined with Warfarin,the control group was given Clopidogrel combined with Warfarin. The patients were followed up for 12 months,the occurrence of total bleeding events（ intracranial hemorrhage or clinical visible bleeding） and adverse cardiovascular events（ Recurrence of myocardial infarction,stent thrombosis,PCI again,ischemic stroke,vascular embolization associated or cardiac ischemic death） of the two groups were observed and compared. Results The incidence of adverse cardiovascular events showed no significant differences（ T group 9. 1% VS. C group 10. 9%,P = 0. 749） between the two group. And the total incidence of bleeding events also showed no significant differences（ T gourp 14. 5% VS. C group 12. 7%,P = 0. 779）. Conclusion Comparing with combined clopidogrel and warfarin,the efficacy and safety of dual antithrombotic therapy with ticagrelor and warfarin are similar in coronary heart disease patients complicated with atrial fibrillation.
出处
《医药论坛杂志》
2016年第2期65-66,69,共3页
Journal of Medical Forum
关键词
替格瑞洛
华法林
冠心病
房颤
Ticagrelor
Warfarin
Coronary heart disease
Atrial fibrillation
